Metacrine, Inc. Common Stock
MTCR
MTCR was delisted on the 8th of February, 2023.
5 hedge funds and large institutions have $5.3M invested in Metacrine, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 25 closing their positions.
27% less capital invested
Capital invested by funds: $7.29M → $5.3M (-$1.99M)
83% less funds holding
Funds holding: 29 → 5 (-24)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 25
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$913K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.9M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$1.32M |
| 3 |
Renaissance Technologies
New York
|
-$257K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$114K |
| 5 |
Bank of New York Mellon
New York
|
-$91.4K |
MTCR Hedge Fund Activity: Q1 2023 in Review
5 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q1 2023, worth a combined $5.3M — down 27% from $7.29M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MTCR and 1 opened new positions — a net loss of 24 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was JBF Capital, opening a new position worth an estimated $913K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.9M sold.
- 5 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q1 2023, down from 29 in Q4 2022.
- Funds reported $5.3M of Metacrine, Inc. Common Stock stock for Q1 2023, down 27% quarter-over-quarter.
- 1 fund opened new Metacrine, Inc. Common Stock positions in Q1 2023 and 25 closed out, a net change of -24 holders.
- The largest Metacrine, Inc. Common Stock buyer in Q1 2023 was JBF Capital, an estimated $913K added.
- The largest Metacrine, Inc. Common Stock seller in Q1 2023 was Tang Capital Management, an estimated $1.9M sold.
Based on aggregated 13F filings for Q1 2023.